Roche Holding AG and Pfizer Inc. are aggressively developing new drugs targeting obesity and type 2 diabetes, aiming to capture growth in the GLP-1 market. Roche's enicepatide shows strong weight loss results in Phase 2 trials with a good safety profile, while Pfizer promotes its monthly-dosed berobenatide as potentially best-in-class based on meta-analysis, though it lacks direct clinical comparisons. The analyst favors Roche due to more comprehensive data and a broader pipeline, suggesting both companies could become major players in obesity treatment. This competition highlights the growing focus on cardiometabolic health in pharma portfolios.
Pfizer remains an undervalued stock that has underperformed the market but increased 2% since the last analysis. It is viewed as a defensive holding that provides income and helps offset risks related to AI in a diversified portfolio. Despite recent ...
Pfizer is currently undervalued, trading at just over 8 times its projected 2026 earnings and offering a 7% dividend yield. Its core business, excluding COVID-related drugs, grew 7% in Q1, while new products, especially from its acquisition of Seagen...
